menu
    • menu

    Company profile for Ollin Biosciences

    NEW Drugs in Dev: 1
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ollin Biosciences is a clinical-stage biopharmaceutical company committed to developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what's possible in ophthalmology. The company's lead clinical-stage program, OLN324, is a higher potency VEGF/Ang2 bispecific antibody in a fully-recruited head-to-head study versus ...
    Ollin Biosciences is a clinical-stage biopharmaceutical company committed to developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what's possible in ophthalmology. The company's lead clinical-stage program, OLN324, is a higher potency VEGF/Ang2 bispecific antibody in a fully-recruited head-to-head study versus faricimab in wet AMD and DME, with topline data expected in Q1 2026.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ollin BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Austin, Texas
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ollin.bio/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ollin Shows Superior Results vs Vabysmo in Eye Disease Study
    Ollin Shows Superior Results vs Vabysmo in Eye Disease Study

    08 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260108162925/en/Ollin-Biosciences-Announces-Positive-Topline-Data-with-Superior-Outcomes-from-a-Randomized-Head-to-Head-Study-of-OLN324-Compared-to-Faricimab-Vabysmo-in-Diabetic-Macular-Edema-and-Wet-Age-Related-Macular-Degeneration

    BUSINESSWIRE
    08 Jan 2026
    Share Share
    Ollin Eyes Phase 3 After Topping Vabysmo In Early-Stage Trial
    Ollin Eyes Phase 3 After Topping Vabysmo In Early-Stage Trial

    08 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ollin-eyes-phase-3-after-topping-vabysmo-head-head-trial-ollins-bispecific-antibody-tops

    FIERCE BIOTECH
    08 Jan 2026
    Share Share
    Ollin Biosciences Presents at 44th J.P. Morgan Healthcare Conf
    Ollin Biosciences Presents at 44th J.P. Morgan Healthcare Conf

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251217962207/en/Ollin-Biosciences-to-Present-at-the-44th-Annual-J.P.-Morgan-Healthcare-Conference-on-Tuesday-January-13

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    Addition Debuts $100M Fund for Rare Disease One-Time Therapies
    Addition Debuts $100M Fund for Rare Disease One-Time Therapies

    17 Dec 2025

    // BIOSPACE

    https://www.biospace.com/business/addition-debuts-with-100m-to-advance-one-time-therapies-for-rare-chronic-diseases

    BIOSPACE
    17 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search